Company / EPS (Diluted)
NovaBay Pharmaceuticals, Inc. EPS (Diluted) History
FY2015-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$0.31
FY2020
5-year range
-$0.31 / -$0.31
FY2016-FY2020
Trend
+35.4%
vs FY2019
Sector context
#58 of 204
Health Care
What the data says
At $-0.31, NovaBay Pharmaceuticals, Inc.'s eps (diluted) ranks #58 of 204 in the Health Care sector. Improved from $-0.46 to $-0.31 over the past 2 years.
Based on SEC 10-K filings.
-0.31 in FY2020.
Improved from $-0.46 to $-0.31 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#58 of 204 in Health CareTop 28% of 204This company -$0.31 Sector average -$1.03
▼
+70.0% above sector average
Key checks
Key Insights
- In FY2020, eps (diluted) increased 35.4% year-over-year.
- Ranks #58 out of 204 companies in the Health Care sector.
- Lowest eps (diluted) in the period was in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.51 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | -$0.31 | +35.4% |
| FY2019 | -$0.48 | -4.3% |
| FY2018 | -$0.46 | +93.3% |
| FY2017 | -$6.82 | +10.8% |
| FY2016 | -$7.65 | +27.2% |
| FY2015 | -$10.51 | -4279.2% |
As of FY2020 · SEC 10-K · Updated Feb 28, 2026